Medical Oncologist
CION Cancer Clinics
FGFR2 fusions in bile duct cancer: what the result means for treatment | CION Cancer Clinics
An FGFR2 fusion is a change found in some bile duct cancers that start inside the liver. If your tumour has one, FGFR inhibitor tablets may become an option, usually after first-line chemotherapy. This page explains what the fusion is, how the tumour is tested, who these medicines suit and who they do not, and what to ask your oncologist. At CION Cancer Clinics in Hyderabad, our oncologists explain liver cancer in plain words and plan care around you and your family.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
The short answer
What does an FGFR2 fusion mean for bile duct cancer treatment?
An FGFR2 fusion is a change found inside some bile duct cancers that start within the liver. When it is present, a group of tablets called FGFR inhibitors can be an option, usually after the first chemotherapy has stopped working.
This page is about intrahepatic cholangiocarcinoma, a cancer of the small bile ducts inside the liver. It is a primary liver cancer, not cancer that spread from somewhere else. It is also different from the commoner liver cancer, hepatocellular carcinoma (HCC). If you are not sure which one your report describes, start with primary versus secondary liver cancer.
What a fusion actually is
Inside the tumour, two genes have broken and joined end to end. The new joined gene keeps a growth switch, called FGFR2, permanently turned on. The cancer cells come to depend on that switch. FGFR inhibitors are designed to block it.
How common it is
Only a minority of intrahepatic bile duct cancers carry an FGFR2 fusion. It is found far less often in bile duct cancers outside the liver or in gallbladder cancer. That is why the tumour has to be tested. Nobody can tell from a scan or a blood report whether it is there.
An FGFR2 fusion is found only in the tumour. It was not inherited and it cannot be passed to your children.What the result changes
If the test finds an FGFR2 fusion, what happens next?
A positive result opens a door. It does not replace the usual first treatment, and it does not decide the plan on its own.
First treatment usually stays the same
For bile duct cancer that cannot be removed, the first treatment is usually chemotherapy with gemcitabine and cisplatin, often combined with an immunotherapy drug. The FGFR2 result is kept ready for later. Read more in chemotherapy and immunotherapy for biliary cancer.
A tablet option for second line
If the cancer grows during or after that first treatment, an FGFR inhibitor becomes a real choice. Pemigatinib and futibatinib are the names you are most likely to hear.
What the team weighs
- How well your liver is working
- Your strength and daily activity
- Eye health and blood phosphate levels
- Whether the medicine can be obtained
A clinical trial may fit
Newer FGFR medicines are still being studied. A fusion result is often what makes someone eligible for a trial. A trial is a choice to consider, never an obligation.
It does not change surgery
If the tumour can be removed, surgery is still the main treatment. The fusion result matters mostly if the cancer returns or cannot be operated on.
Not sure whether this applies to you?
Ask an oncologistGetting the test
How is an FGFR2 fusion tested for?
The tissue already taken
The test usually uses the tumour sample from your biopsy or operation. The pathology laboratory keeps it as a small wax block. A new biopsy is needed only when too little tumour was left.
A broad panel, not a single gene
Most oncologists order a panel test, often called next-generation sequencing. It looks for FGFR2 fusions, IDH1 changes, HER2 and others in one go. Tests that read RNA tend to pick up fusions more reliably. See why every biliary cancer should be molecularly tested.
Blood tests have limits
A blood-based test, sometimes called a liquid biopsy, can help when no tissue is available. It can miss fusions. A negative blood result does not rule one out.
The tumour board reads it
The report goes to your oncologist and the tumour board, who decide whether it changes the plan now or later. CION arranges testing through accredited laboratory partners and explains the result to you.
On your report
What do the words on an FGFR2 report mean?
- FGFR2 fusion or rearrangement
- The gene has broken and joined another gene. This is the change the current FGFR tablets were approved for.
- Fusion partner
- The name of the second gene, such as BICC1. Many different partners exist. The partner usually does not change the choice of medicine.
- FGFR2 mutation or amplification
- A different kind of change in the same gene. These do not respond in the same way, so ask your oncologist which kind your report shows.
- Somatic
- Found only in the tumour, not in the rest of your body. Almost all FGFR2 fusions are somatic.
- Actionable
- A change for which a medicine or a trial exists. It is a laboratory word, not a promise that the medicine will work.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Who this does not suit
Who are FGFR inhibitors not right for?
These medicines help only people whose tumour carries the right change. Without an FGFR2 fusion or rearrangement on a proper test, they are not expected to help. That includes most people with HCC and most people whose liver cancer spread from the bowel, breast or elsewhere.
When the body or liver cannot take it
Someone who is very unwell, mostly in bed, or whose liver is failing may be harmed more than helped. Comfort-focused care can then be the kinder choice, and it can run alongside any treatment.
The side effects that need watching
FGFR inhibitors commonly raise the phosphate level in the blood. They can cause dry eyes, fluid under the retina, nail and skin changes, mouth sores and hair thinning. Regular blood tests and eye checks are part of treatment. People with existing eye disease need careful planning. The details live on our page about FGFR-targeted treatment.
When it stops working
Most tumours eventually find a way around the block. When scans show growth again, the team looks at other options or trials.
Being straight with you
What this page cannot tell you
It cannot tell you whether your tumour has an FGFR2 fusion. Only a laboratory test on tumour tissue answers that. It also cannot tell you whether an FGFR inhibitor is the right step for you, or how long it might control the cancer. Those answers depend on your scans, your liver function and your earlier treatment.
Availability in India changes
Whether a particular FGFR medicine is approved and sold in India, and at what cost, changes over time. Some may be reachable only through import or a trial. Your oncologist should check the current position before you plan around any one drug.
Who can answer properly
A medical oncologist who has seen your full report, ideally with the tumour board, is the right person. If you were never tested, ask why. A second opinion on the plan is reasonable and common.
Bring the molecular report, the pathology report and the latest scans to any consultation.Questions we are asked
Common questions about FGFR2 fusions
Is an FGFR2 fusion good news or bad news?
Neither, exactly. It describes how the tumour grows. Its main practical value is that it opens a targeted treatment option for later, which people without the fusion do not have. Your outlook still depends mostly on the stage of the cancer and your general health.
Can I start the tablet instead of chemotherapy?
Usually not. Chemotherapy, often with immunotherapy, remains the standard first treatment for advanced bile duct cancer. FGFR inhibitors are generally used once that has stopped working. Sometimes a trial tests them earlier, and your oncologist can tell you whether one is open to you.
Should my children be tested for FGFR2?
No. An FGFR2 fusion arises inside the tumour during life. It is not in your other cells and cannot be inherited. If a doctor separately suspects an inherited condition, that needs a different blood test and a genetic counsellor.
My first test did not mention FGFR2. Should I ask again?
Yes. Some earlier tests covered only a few genes, or used a method that misses fusions. Ask your oncologist whether a broader panel, preferably one that reads RNA, can be run on the stored tissue block.
Do FGFR inhibitors affect the eyes?
They can. Dry eyes are common, and fluid can collect under the retina. You will usually have an eye examination before starting and regular checks after. Tell your team at once about blurred vision, flashes or a shadow in your sight.
Why does my phosphate level keep being checked?
Blocking FGFR raises phosphate in the blood. High levels can deposit in soft tissues over time. Your team checks it often and may adjust your diet, add a binder medicine or pause the tablet. Never change or stop the tablet on your own.
Does this apply to gallbladder cancer?
Rarely. FGFR2 fusions are found mainly in bile duct cancer that starts inside the liver. Gallbladder cancer is still tested, because other changes such as HER2 may be found. See our gallbladder cancer section.
Where do I start if I have this diagnosis?
Gather the biopsy report, any molecular report and your recent scans. Call the CION helpline and a medical oncologist can review them with the tumour board. They will tell you whether more testing is worth doing and what your options are.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Bile Duct Cancer Targeted Therapy
- National Cancer Institute — Bile Duct Cancer Treatment
- Cancer Research UK — Treatment for bile duct cancer
- National Cancer Institute — Targeted Therapy for Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Why every biliary cancer should be molecularly testedThe full list of changes the test looks forIDH1 mutations in bile duct cancerThe other common targetable changeHER2, BRAF and MSI in bile duct cancerRarer findings that also open optionsFGFR-targeted treatmentHow the tablets work and their side effects
Talk to us
Has your bile duct cancer been tested for FGFR2?
Send us the biopsy and any molecular report, and a medical oncologist will tell you whether further testing or a targeted option is worth discussing. One helpline serves every CION centre.